20
Mylan Laboratories Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIVASTIGMINE USP (PROCESS II), with a corresponding US DMF Number 26499.
Remarkably, this DMF maintains an Active status since its submission on September 26, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of July 08, 2013, and payment made on February 19, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II